ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) antibodies administrated in combination with stereotactic body radiotherapy (SBRT) in patients with metastatic squamous cell carcinoma of head and neck, lung, oesophageus, cervix, vagina, vulva or anus.

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Institut Gustave Roussy

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

20 Jun 2017 → 24 Feb 2025

Decision date (initial)

2024-07-09

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

External identifiers

EU CT number

2024-514920-18-00

EudraCT number

2016-003293-40

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Safety, Efficacy, Pharmacogenomic

- Preliminary steps (safety runs): To evaluate the safety of Durvalumab +/- Tremelimumab in combination with SBRT
- Phase II: To evaluate the abscopal response rate following treatment with Durvalumab +Tremelimumab in combination with SBRT

Secondary objectives 2

1. To describe the clinical efficacy of the combination both on the irradiated lesion and on the non-irradiated lesions
2. To evaluate the safety and tolerability of Durvalumab and Tremelimumab combined to radiotherapy within the 6 months after completion of radiotherapy

Conditions and MedDRA coding

Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 15

1. Male or Female patients ≥18 years of age or older.
2. Histologically or cytologically proven metastatic squamous cell carcinoma (from head and neck, oesophagus, lung, cervix, vagina, vulva or anus) with the following features:  Previously treated with at least one prior regimen (chemotherapy, signal transduction inhibitors or radiotherapy)  To be treated with radiotherapy at primary tumor site or metastatic site or menacing metastatic site. o The sites of metastases allowed are: soft tissue, peripheral lung, and liver. o Patients with brain and bone metastasis to be treated with radiotherapy are not allowed. Patients with asymptomatic brain metastasis can be included o The total tumor volume to be irradiated must not exceed 400 cc.
3. At least one tumor lesion must be accessible to radiation therapy and at least another tumor site can be spared from radiation therapy (unirradiated site).
4. At least one unirradiated and one irradiated tumor site must be accessible to tumor biopsy.
5. Known availability of an archived block
6. The irradiated and unirradiated tumor sites must be mesurable as per RECIST 1.1
7. Patients must have no history of previous radiation therapy within the body area to be irradiated.
8. Minimal wash-out periods from previous treatments to C1D1 must be  Any investigational agent > 4 weeks  Bevacizumab > 6 weeks  Chemotherapy > 4 weeks  TKI > 4 weeks  RANK ligand agonists > 6 weeks  Immunosuppressive medication > 28 days, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceeding 10 mg/day of prednisone, or an equivalent corticosteroid  Live attenuated vaccination > 30 days
9. WHO 0-1, Performance Status ECOG of 0-1
10. Patients must have adequate organ function defined as follows:  Absolute neutrophil count of ≥ 1500/mm3,  Platelet count≥ 100,000/mm3,  Hemoglobin > 9 g/dL,  Bilirubin ≤ 1.5 times the institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.  Serum ALT and AST ≤2.5 ULN (or if liver metastases are present must be ≤ 5x ULN)  Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (see formula in section 4.1).
11. Patients must be free of significant comorbid conditions that would preclude safe administration or completion of protocol therapy.
12. Female patients must either be of non-reproductive potential (ie, post-menopausal ≥ 12 months with no menses without an alternative medical cause OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry (within 72 hours before study drug start)
13. Fertile men with a female partner of childbearing potential must agree to use male codom plus spermicide and childbearing potential women must have agreed to use at least one highly effective contraceptive method during treatment on this trial and for up to 180 days after the last of dose of Durvalumab + Tremelimumab or 90 days after the last dose of Durvalumab monotherapy, whichever is the longer period
14. Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol
15. Patients must be affiliated to a social security system or beneficiary of the same

Exclusion criteria 13

1. Any situation where the irradiation of the target site would imply re-irradiation of a formerly irradiated tumor site.
2. Patients with any concurrent severe and/or uncontrolled disease which could compromise participation in the study including:  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia’s Correction  Active or prior documented autoimmune disease within the past 2 years. Of note, patient with vitiligo, Grave’s disease or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Patients with type 1 diabetes or hypothyroiditism stable under treatment or not requiring systemic treatment are eligible.  Active or prior documented inflammatory bowel disease (eg Crohn’s disease, ulcerative colitis)  History of primary immunodeficiency  Severe chronic or acute infection such as chronic HBV, HCV and HIV1, 2 infection, active tuberculosis infection  Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active non-infectious pneumonitis  History of allogenic organ transplant  Uncontrolled diabetes,  Prior history of active bleeding diathesis or patients taking an oral vitamin K antagonist (except low-dose Coumadin (warfarin sodium))  Symptomatic congestive heart failure,  Uncontrolled hypertension,  Unstable angina pectoris  Cardiac arrhythmia  Active peptic ulcer disease or gastritis,  Any psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent  Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the sponsor. Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen. Patients with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.  Chronic treatment with corticosteroids or another immunosuppressant
3. Patients with tumors that invade major vessels, as shown unequivocally by imaging studies
4. Patients with central lung metastasis (i.e within 2 cm from hilum) that are cavitary as shown unequivocally by imaging studies
5. Patients with a history of gross hemoptysis (bright red blood of ½ teaspoon or more per episode of coughing) ≤ 3 months prior enrolment
6. Major surgery within the last 4 weeks prior to entering the study
7. Persisting significant toxicities related to prior treatments i.e. ≥ Grade 2 AE according to CTCAE V4.03 except alopecia and biological values defined in inclusion criteria I10.
8. Current or planned use of forbidden concomitant medications :  Any investigational anticancer therapy not specified in this protocol  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.  Immunosuppressive medications including, but not limited to systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, and TNF-α  blockers. Use of immunosuppressive medications for the management of investigational product-related AEs or in subjects with contrast allergies is acceptable. In addition, use of topical, inhaled and intranasal corticosteroids is permitted.  Live attenuated vaccines within 90 days of Durvalumab dosing or within 180 days of Durvalumab and Tremelimumab dosing. Inactivated vaccines, such as the injectable influenza vaccine, are authorized.
9. Any prior Grade ≥ 3 irAE while receiving previous immunotherapy agent or any unresolved irAE > Grade 1.
10. Prior exposure to any anti-PD-1 or anti-PD-L1 or anti-CTLA4 antibody
11. Known allergy or hypersensitivity to humanized antibodies
12. Pregnant or breastfeeding women
13. Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Phase I: dose limiting toxicities (AE assessed using CTCAE v 4.03)
2. Phase II: CT-SCAN evaluation outside the field of focal radiotherapy

Secondary endpoints 2

1. RECIST 1.1 and irRC
2. Adverse events based on CTCAE-V4

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Gustave Roussy

Sponsor organisation

Institut Gustave Roussy

Address

114 Rue Edouard Vaillant

City

Villejuif

Postcode

94800

Country

France

Scientific contact point

Organisation

Institut Gustave Roussy

Contact name

Bureau projet Promotion- DRC-Regulatory Affairs Officer

Public contact point

Organisation

Institut Gustave Roussy

Contact name

Bureau projet Promotion- DRC-Regulatory Affairs Officer

Locations

1 EU/EEA country · 2 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 4 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications